Key facts
- Medorion’s last known valuation is $18.5M (Jul 2021).
- It has raised $9.6M; the latest was Merger/Acquisition in Jun 2023.
- Notable investors include iAngels, 10D, Gandyr Investments, I-Next Capital, IBM Alpha Zone Accelerator — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Medorion
- ·The full record, as it builds
Funding rounds
No funding rounds for Medorion are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Medorion
Developer of a health management platform designed to facilitate patient adherence according to medical guidelines. The company's platform utilizes artificial intelligence, clinical data, and behavioral science to identify the underlying health issues of each member to segment the population and create a distinctive strategy to engage each member, enabling health organizations to analyze claims data to uncover individual member behaviors based on AI algorithms and apply these insights everywhere through seamless omnichannel integration.
- Sector
- Healthcare
- HQ
- Tel Aviv, Israel
- Founded
- 2017
- Employees
- 42
- Website
- medorion.com/
- Ownership
- Privately Held (backing)
Medorion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medorion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medorion in its N-PORT filings yet. We sweep new filings monthly.